Aditi Mehta, an esteemed antitrust economist, joins Analysis Group, enhancing their competition policy expertise and broadening regulatory capabilities.

This article explores how health economics and outcomes research is reshaping the evaluation of cell and gene therapies for rare diseases, enhancing accessibility and patient outcomes.

Analysis Group reveals a groundbreaking framework to assess the comprehensive value of therapies across multiple medical indications, enhancing patient access and care.

Analysis Group officially names Pierre Cremieux as its new CEO, taking over from Martha Samuelson, who remains Chairman. Explore this leadership transition.